CClinicalTrials.gg
CompletedNCT05445453PMUpdated Feb 23, 2024

Museum Prescription by a Physician for a Visit to the MBAM

An interventional study of Museum visit in Quality of Life and Social Isolation, sponsored by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

In recent years, museums have participated in the patient care journey by using art to enhance their quality of life and well-being. Since 2015, the Montreal Museum of Fine Arts (MMFA) and Dr. Beauchet have developed an Action-Research program exploring the effects of participatory art activities for community elders conducted at the MMFA, known as the Arts \& Longevity Lab (ALL). The mandate of ALL is to improve the well-being, quality of life and health (i.e. mental and physical state) of individuals and patients through the practice of visual arts activities (i.e. arts that produce objects perceived by the eyes).

Since 2019, the MMFA has developed in collaboration with Médecins Francophones du Canada museum visits prescribed by a primary care physician as a new intervention. Today, it is necessary to improve the knowledge on the effects of this museum visit prescription

The overall objective of this study is to examine the effects of a visit to the MMFA prescribed by a primary care physician on the mental health (well-being and quality of life) of patients living in Montreal.

02

Conditions studied

  • Quality of Life
  • Social Isolation

Keywords

  • Arts
  • Well-being
  • Mental Health
03

In context

Lead sponsor

Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal is the lead sponsor of 11 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • age 18 and over
  • having Internet access at home with an electronic device (computer, keyboard, or smartphone)
  • having no dementia
  • speaking English or French
  • committing to visiting the museum within 3 months of the prescription.

Exclusion criteria

Exclusion Criteria:

  • individuals participating in a clinical trial at the same time, to avoid interference with the results of the intervention being studied in this protocol
  • individuals with dementia. There are no tests for dementia. The physicians involved in the pre-recruitment process are aware of the cognitive status of their patients. Therefore, they will be able to avoid offering the study to a patient with dementia if such a diagnosis appears in the medical file.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Intervention

    Physicians participating in the research project will be able to prescribe a visit to the Museum to any of their patients for whom they deem this museum prescription necessary. Only patients who meet the inclusion criteria will be offered to participate in the research. If patients refuse or do not meet the inclusion criteria, they may be prescribed a museum visit but will not be offered the study. After obtaining informed consent, the patient will be asked to complete 2 sets of self-administered questionnaires: in the 2 days prior to the visit and in the 2 days following the MBAM visit.

    Other: Museum visit

Interventions

  • OtherMuseum visit

    The intervention is a visit of the MMFA. This visit can be done alone or accompanied. The visit of the MMFA is free for the patient.

06

What researchers measure

Primary outcomes

  1. Quality of life

    Quality of life will be assessed using the EuroQol-5D (EQ-5D). EuroQol-5D is composed of two parts: * a five-question questionnaire with a score per question ranging from 1 (no problem) to 5 (severe problem), so that the sum ranged from 0 (no problem) to 25 (severe problem). * a visual analogue scale on participants' perceived health. This scale is numbered from 0 (i.e., the worst health the participant can imagine) to 100 (i.e., the best health the participant can imagine). This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

    Time frame: 3 months

  2. Well-being

    Well-being will be assessed using the Warwick-Edinburgh Mental Well-being Scale (WEMWBS). The WEMWBS is a validated questionnaire composed by a 14-item positively worded scale and five response categories. It covers most aspects of positive mental health (positive thoughts and feelings). This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

    Time frame: 3 months

Secondary outcomes

  1. Physical Health Status

    Physical health status will be assessed using the CRIUGM Self-AdMinistered questionnaire (CESAM). The CESAM has been previously developed and validated. It is composed of 20 items exploring several domains: * weight loss and its extent; * polypharmacy defined by a number of therapeutic classes taken on a daily basis ≥ 5; * vision, hearing, and memory problems; * use of home support; * 6-item activities of daily living scale, 4-item instrumental activities of daily living scale; * mood assessed * regular physical activity defined as at least 1 hour per week in the past month; * and history of falls in the past 12 months. The CESAM provides two complementary scores: 1. An overall frailty score ranging from 0 to 18 2. A four-stage categorization of frailty This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

    Time frame: 3 months

  2. Social Isolation

    Social isolation will be assessed using the 11-item Duke Social Support Index (DSSI). This index includes two subscales: * social interaction (i.e., frequency of interactions) * subjective support (i.e., satisfaction with emotional support provided). The DSSI score ranges from 11 to 33, with higher scores indicating higher levels of social inclusion. Scores for the 11 items are combined and categorized as low (score ≤26), high (score 27-29), and very high (score 30-33). We will use the mean score of the 11-item DSSI and its breakdown into three categories as the primary outcome. This questionnaire will be completed online on the CRIUGM web platform using an electronic device.

    Time frame: 3 months

  3. Prescribing context

    Researchers will also study the prescribing context. A document will be filled by primary care physicians to give additional informations on the prescribing context such as the date of the prescription and the reason of the prescription.

    Time frame: 3 months

  4. Satisfaction from the visit to the museum

    A short questionnaire will be given to participants to the intervention at the end of the visit to the museum. This questionnaire will give additionnal information on the satisfaction from the visit and whether the visit was made alone or accompanied.

    Time frame: 3 months

07

Study locations

1 site
  • CRIUGM
    Montréal, Quebec H3W 1W5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05445453
Lead sponsor
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Responsible party
Olivier Beauchet (MD, PhD, Senior researcher, Director of laboratory, Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal) — Principal investigator
First posted
Jul 6, 2022
Start date
Jun 27, 2022
Primary completion
Jul 21, 2023
Completion
Dec 22, 2023
Last update
Feb 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion